Results 151 to 160 of about 71,065 (294)

From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics. [PDF]

Signal Transduct Target Ther
Loy CA, Gu Y, Kim SC, Mohagheghi MV, Trask NB, Suarez-Pizarro M, Wagar LE, Benavente CA, Trader DJ.   +8 more
europepmc   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy. [PDF]

Nat Nanotechnol
Han K, Cho YS, Takahashi M, Zhou X, Dobson HE, Hutchings K, Wu Y, Na Y, Xie F, Crowther J, Wu J, Xu J, Lee C, Jasewicz H, Kim Y, Nenwani M, Animasahun O, Wuchu F, Andren A, Wong H, Camp E, Wan Z, Wu Q, Zhang L, Xu C, Dong K, Xu Y, Schwendeman A, Chen GY, Xie Y, Lyssiotis CA, Clasby M, Nagrath D, Lei YL, Moon JJ.   +34 more
europepmc   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Cathepsin Family Proteases in Prodrug Design: Recent Advances. [PDF]

ChemMedChem
Liu H, Zheng M, Ng CS, Loh TP.
europepmc   +1 more source

Clinical Functional Assignment of TPMT and NUDT15 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel

Clinical Pharmacology &Therapeutics, EarlyView.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) TPMT/NUDT15 Pharmacogene Curation Expert Panel (PCEP) conducted a comprehensive review of clinical, laboratory, and computational evidence to determine the clinical function assignments for TPMT and NUDT15 star alleles.
Bailey M. Tibben, Maud Maillard, Victoria M. Pratt, Ann M. Moyer, Debbie M. Figueroa, Michelle Whirl‐Carrillo, Andrea Gaedigk, Gabriele Stocco, Matthias Schwab, Kelly E. Caudle, Jun J. Yang   +10 more
wiley   +1 more source

The Development of Four-Arm PEG-Based Thermoresponsive Dexamethasone Prodrugs for the Treatment of Osteoarthritis Pain. [PDF]

Nanomaterials (Basel)
Deng Y, Arash S, Rong J, Althobaiti SA, Liu S, Ransdell-Green E, Fehringer EV, Wang D.   +7 more
europepmc   +1 more source

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann, Ruy M. Ribeiro, Aurelien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source

Heavy-Atom-Free Dual-Action Dual PACT/PDT action Pt(IV) Prodrug With BODIPY Dimer in Axial Position. [PDF]

ChemMedChem
Bykusov V, Isaeva Y, Akasov R, Egorova T, Mun V, Bunin D, Kuzmin V, Egorov A, Burtsev I, Grishin Y, Rodin I, Vokuev M, Beloglazkina E, Krasnovskaya O.   +13 more
europepmc   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source